The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...
Shares of solid tumor concern Zymeworks Inc. have barely budged since the company obtained its first approval. Click here to ...
With the rising incidence of cancer in India, AstraZeneca India's breast cancer medicine trastuzumab deruxtecan (sold under ...
A NEW breast cancer therapy shown to significantly reduce the risk of cancer recurrence and improve disease-free survival in ...
In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company ...
Indicates growing incidence of cancer among Indian population; five out of top 20 new brand launches are cancer drugs ...
Second, while the company has presented positive findings ... It also allowed patients who did not receive trastuzumab prior. So when you see that 100% disease-free survival (versus 89.4% in ...
AZ booked $540 million from Enhertu in the fourth quarter, a rise of 54%, and $1.99 billion for the full year out of total ...
Hosted on MSN13d
Navigating the cancer crisis: a mother’s fight for affordable treatment amidst rising costsTwenty-four-year-old Caitlyn Micholson is fighting cancer and for a chance to access lifesaving alternative treatment that is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback